Results 91 to 100 of about 1,002,895 (267)

Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini   +13 more
wiley   +1 more source

CSF Levels of NPTX2 Are Associated With Less Brain Atrophy Over Time in Cognitively Unimpaired Individuals

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Neuronal pentraxin 2 (NPTX2) is a synaptic protein involved in synaptic plasticity and regulation of neuronal excitability. Lower baseline cerebrospinal fluid (CSF) NPTX2 levels have been shown to be associated with an earlier onset of mild cognitive impairment (MCI), a pre‐dementia syndrome, even after CSF Alzheimer's Disease (AD)
Juan P. Vazquez   +12 more
wiley   +1 more source

Long-acting relaxin analogues: a novel tool in cardiology

open access: yesFrontiers in Pharmacology
Serelaxin, a recombinant human relaxin, has emerged as a potential therapy for the future treatment of heart failure. However, its effectiveness has been limited by a short half-life and the need for intravenous administration.
Łukasz Wołowiec   +6 more
doaj   +1 more source

Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment [PDF]

open access: diamond, 2021
Andrea Sauer   +3 more
openalex   +1 more source

A Comprehensive Overview of the Clinical, Electrophysiological, and Neuroimaging Features of BPAN: Insights From a New Case Series

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Neurodegeneration with brain iron accumulation (NBIA) comprises a genetically and clinically heterogeneous group of rare neurological disorders characterized particularly by iron accumulation in the basal ganglia. To date, 15 genes have been associated with NBIA.
Seda Susgun   +95 more
wiley   +1 more source

New bearings in pharmacotherapeutic strategies: Pharmacogenetics and gene therapy [PDF]

open access: yesVojnosanitetski Pregled, 2007
Grbović Leposava   +4 more
doaj   +1 more source

Celebrating milestones and embracing innovation: the next chapter for Drugs in Context

open access: yesDrugs in Context
The Senior Editors of Drugs in Context are excited to announce that the journal received its first Impact Factor of 2.8 in the 2025 Edition of Journal Citation Reports1 by Clarivate. This represents a significant metric milestone, and the result of years
Sarah L Anderson   +2 more
doaj   +1 more source

Decreased Serum 5‐HT: Clinical Correlates and Regulatory Role in NMJ of MG

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Although 5‐Hydroxytryptamine (5‐HT) indirectly stimulates muscle contraction and participates in regulating Acetylcholine receptor (AChR) cluster homeostasis in cellular, animal, and clinical studies, evidence regarding its potential to modulate muscle contraction in myasthenia gravis (MG) remains limited.
Xinru Shen   +18 more
wiley   +1 more source

RAB39B Related Parkinsonism in an Italian Family: A Unique Use of Advanced Therapies

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Parkinson's disease (PD) is a neurodegenerative disorder that may sometimes be caused by deleterious genetic variants. Among them, RAB39B polymorphisms are known as rare causes of early‐onset PD associated with intellectual disability (Waisman's syndrome).
Caterina Del Regno   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy